Haematology
Heparin-Induced Thrombocytopenia (HIT)
4Ts pre-test probability, ELISA + functional assay, immediate non-heparin anticoagulant (argatroban / fondaparinux), avoid platelet transfusion.
Source: BSH 2012; ASH 2018
Step 1 of ~3
info
Suspect — 4Ts Score
Falling platelet count + recent heparin exposure (UFH > LMWH, 4–14 days post-exposure typically). Paradoxically thrombotic — DVT/PE/arterial.
4Ts score:
• Thrombocytopenia: >50% fall + nadir ≥20 (2); 30–50% fall OR nadir 10–19 (1); <30% fall OR nadir <10 (0).
• Timing onset: 5–10 days OR <1 day with heparin in last 30 days (2); >10 days OR fall <5 days but unclear prior exposure (1).
• Thrombosis OR sequelae: new thrombosis / skin necrosis (2); progressive / recurrent / silent / cutaneous reaction (1).
• OTher cause: none apparent (2); possible (1); definite (0).
Score: ≤3 low probability (1%), 4–5 intermediate (10%), ≥6 high (>50%).
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Unfractionated Heparin (ACS / PCI) · Anticoagulant / ACS / PCI
- Unfractionated Heparin (IV) · Anticoagulant — ACS / PE / Thrombus
- Unfractionated Heparin (UFH) · Anticoagulant (parenteral)
- Heparin (unfractionated) · Anticoagulant
- Argatroban Monohydrate · Direct Thrombin Inhibitor (Parenterally Administered Anticoagulant)
- Low Molecular Weight Heparin (Pregnancy VTE) · Anticoagulant — VTE Treatment and Prophylaxis in Pregnancy
Pathways
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Splenomegaly Workup · BSH; BMJ Best Practice
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158
- Sickle Cell Crisis · BSH 2021 / BCSH
- Neutropenic Sepsis · NICE CG151 2012 / ESMO
Decision support only. Always apply local guidelines and clinical judgement.